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An 80-year-old man, known for years to have chronic renal failure due to retroperito-neal fibrosis, was referred for worsening dyspnea. The cardiac magnetic resonanceshowed moderate pericardial effusion and a right atrial wall thickness of approximately
2 cm, sparing the fossa ovalis (A, Online Video 1). The poor contrast uptake of the atrial wall
was suggestive for an infiltrative disease. Cardiac Erdheim-Chester disease, a non-Langherans
cells histiocytosis, was confirmed by the finding of CD 68 histiocytes on a previous perirenal
tissue biopsy specimen (B, labeled in orange), and of the peculiar radiographic long bones os-
teosclerosis (C).
Interferon-alpha 2a was administered 3 times a week for 1 year. The C-reactive protein level
decreased from 14 to 0.28 mg/dl. The significant clinical improvement was supported by the
follow-up cardiac magnetic resonance study (D, Online Video 2), showing an unexpected re-
duction in right atrial wall thickness and in pericardial effusion.
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